SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (2467)4/19/1997 10:20:00 AM
From: WWS   of 4342
 
Richard, exploring PRLN's latest annual report (12/30/96) at Edgar site I uncovered the following quote about their business intentions:
"The Company's strategy is to add value to the product development
process by concentrating its efforts on the highly specialized area of
early-stage compound development, generally discovery through
preclinical toxicology mode of action, pharmacology and Phase I
clinical trials." Further reading therein discloses that the initial screening process consists of two stages, and is a process that PRLN is still working to "perfect". It is clear to me that PRLN recognized that they could not realistically expect to "hand off" to a paying partner a candidate compound only on the basis that it had passed the company's preliminary in vitro screening process. Another company hoping to carry on where PRLN left off would have to have pockets deep enough to take the research at least through Phase 1 trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News